BriaCell Therapeutics (BCT) Competitors

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability.

Which has higher valuation and earnings, HBP or BCT?

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helix BioPharma	N/A	N/A	-C$50.55M	-C$0.95	-0.98
BriaCell Therapeutics	N/A	N/A	-C$2.37M	-C$1.32	-3.19

Does the MarketBeat Community believe in HBP or BCT?

Helix BioPharma received 65 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.

Company	Underperform	Outperform
Helix BioPharma	Outperform Votes 66 63.46%	Underperform Votes 38 36.54%
BriaCell Therapeutics	Outperform Votes 1 100.00%	Underperform Votes No Votes

Does the media prefer HBP or BCT?

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company	Overall Sentiment
Helix BioPharma	Neutral
BriaCell Therapeutics	Neutral

Do institutionals and insiders hold more shares of HBP or BCT?

15.0% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Comparatively, 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, HBP or BCT?

Helix BioPharma has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.

Is HBP or BCT more profitable?

Helix BioPharma's return on equity of 1,803.57% beat BriaCell Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Helix BioPharma	N/A	1,803.57%	-279.98%
BriaCell Therapeutics	N/A	536.29%	-122.71%

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 10 factors compared between the two stocks.